{"entity":{"id":"nct06079983","kind":"trial","name":"JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects","aka":[],"tldr":"A phase 3 trial testing JSKN003 in HR-positive / HER2-negative breast cancer, now recruiting.","summary":"JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects is a phase 3 interventional study registered as NCT06079983, led by Jiangsu Alphamab Biopharmaceuticals, and recruiting on the registry. Official title: A Phase 3, Multicenter, Randomised, Open-Label, Active-Controlled Trial Of JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects. Planned enrolment is 400 participants (estimated). The study started in 2023-12-01 and primary completion is expected in 2026-04-01. No results have been posted on ClinicalTrials.gov.","status":"recruiting","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT06079983","url":"https://clinicaltrials.gov/study/NCT06079983"}],"tags":["ctgov-ingest"],"related":[],"cancers":["breast-hr-positive","her2-low-metastatic-breast-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["jskn003"],"companies":["alphamab"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06079983","phase":"3","setting":"A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Trial Of JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects","sponsor":"Jiangsu Alphamab Biopharmaceuticals","started":"2023-12-01","startedType":"actual","enrolled":400,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06079983/","neighbours":{"cancer":[{"id":"her2-low-metastatic-breast-cancer","kind":"cancer","name":"HER2-low and HER2-ultralow metastatic breast cancer","route":"/cancers/her2-low-metastatic-breast-cancer/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"}],"drug":[{"id":"jskn003","kind":"drug","name":"JSKN003","route":"/drugs/jskn003/"}],"company":[{"id":"alphamab","kind":"company","name":"Alphamab Oncology","route":"/companies/alphamab/"}]}}